FENNEC PHARMACEUTICALS INC.
FENNEC PHARMACEUTICALS INC. (FENC): 1 pipeline candidate · 1 upcoming catalyst · ~10 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.5 months
D/E 0.91 · 3% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~4761d
0 buys · 8 sells (180d)
A transparent, data-derived signal for FENNEC PHARMACEUTICALS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$317.5M
Cash
$40.2M
Quarterly Burn
$15.2M
Runway
9.5 mo
Revenue
$15.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| pedmark | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$53.7M
| Holder | Shares | Value |
|---|---|---|
| southpoint capital advisors lp | 2,744,741 | $16.9M |
| vanguard capital management llc | 1,794,288 | $11.0M |
| blackrock, inc. | 1,368,176 | $8.4M |
| geode capital management, llc | 371,738 | $2.3M |
| state street corp | 359,055 | $2.2M |
| morgan stanley | 211,108 | $1.3M |
| vanguard portfolio management llc | 168,473 | $1.0M |
| citadel advisors llc | 153,610 | $945K |
| northern trust corp | 152,123 | $936K |
| lion point capital, lp | 112,434 | $691K |
Showing top 10 of 86 institutional holders of FENNEC PHARMACEUTICALS INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in FENNEC PHARMACEUTICALS INC.'s pipeline?
FENNEC PHARMACEUTICALS INC. (FENC) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is FENNEC PHARMACEUTICALS INC.'s lead drug candidate?
FENNEC PHARMACEUTICALS INC.'s most advanced tracked candidate is pedmark (Approved) for reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.
What is FENNEC PHARMACEUTICALS INC.'s next catalyst?
FENNEC PHARMACEUTICALS INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: PEDMARK" — expected July 1, 2039.
What is FENNEC PHARMACEUTICALS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, FENNEC PHARMACEUTICALS INC. has approximately 9.5 months of cash runway.
What is FENNEC PHARMACEUTICALS INC.'s market capitalization?
FENNEC PHARMACEUTICALS INC.'s market capitalization is approximately $317.5M.
Get the full picture on FENNEC PHARMACEUTICALS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.